Portola’s andexanet alfa reverses Eliquis anticoagulant effect
A Phase III clinical trial has found that Portola Pharmaceuticals' (Nasdaq: PTLA) andexanet alfa reverses the effects of the anticoagulant apixaban, with the news leading to a 4.1% rise to $28.50 in the company’s share price.
Results from the first part of the Phase III ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies were announced by Portola and partners Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) - which market the blood thinner Eliquis (apixaban) - showing the product produced rapid and nearly complete reversal (by around 94%, p value < 0.0001) of the anticoagulant effect of Eliquis in healthy volunteers aged 50-75.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze